ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for misleading statements made during the Class Period from May 9, 2024, to May 8, 2025, potentially affecting investors' financial interests [1][4]. Group 1: Lawsuit Details - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to longer timelines and higher patient drop-offs [4]. - It is claimed that these issues resulted in increased costs and decreased revenue for Iovance, contradicting the company's positive statements about its business and operations [4]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors in this case, highlighting its track record of recovering significant amounts for investors [5]. - Investors are advised to select qualified legal counsel with a proven history in leadership roles within class actions [5]. - The firm has achieved notable settlements, including over $438 million for investors in 2019 alone, and has been consistently ranked among the top firms in securities class action settlements [5].